THE WOODLANDS, Texas,
Aug. 3 /PRNewswire-FirstCall/ --
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical
company focused on discovering breakthrough treatments for human
disease, announced today that it will release its second quarter
2010 financial results on Monday, August 9,
2010 before the financial markets open. Lexicon
management will hold a conference call to discuss its clinical
development progress and financial results for the quarter at
11:00 a.m. Eastern Time that same
day.
The dial-in number for the conference call is 888-220-1244
(within the US/Canada) or
706-679-5615 (international). The conference ID for all
callers is 92435005. Investors can access a live webcast of
the call at www.lexpharma.com. An archived version of the
webcast will be available on the website through August 16, 2010.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
and developing breakthrough treatments for human disease.
Lexicon currently has four drug candidates in mid-stage
development for diabetes, irritable bowel syndrome, carcinoid
syndrome and rheumatoid arthritis, all of which were discovered by
Lexicon's research team. Lexicon has used its proprietary
gene knockout technology to identify more than 100 promising drug
targets. Lexicon has focused drug discovery efforts on these
biologically-validated targets to create its extensive pipeline of
clinical and preclinical programs. For additional information
about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors that may cause Lexicon's actual results to
be materially different from any future results expressed or
implied by such forward-looking statements. Information
identifying such important factors is contained under "Factors
Affecting Forward-Looking Statements" and "Risk Factors" in
Lexicon's annual report on Form 10-K for the year ended
December 31, 2009, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright g. 3 PR Newswire